These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 18798735)
21. Ian Tomlinson. Tomlinson I Nat Rev Drug Discov; 2016 Mar; 15(3):154. PubMed ID: 26893183 [No Abstract] [Full Text] [Related]
22. Ask the experts: future of the pharmaceutical industry. Interview by Future Medicinal Chemistry. Cottens S; Eaton M; Fuhr J; Geary S; Johnson DS; Li G; Raveglia L; Robertson GM; Westwell A Future Med Chem; 2011 Nov; 3(15):1863-72. PubMed ID: 22023030 [TBL] [Abstract][Full Text] [Related]
23. The role of discovery DMPK scientists in industry: where do we go from here? Moriwaki T Drug Metab Pharmacokinet; 2012; 27(2):169-70. PubMed ID: 22531680 [No Abstract] [Full Text] [Related]
24. Translational regenerative medicine research: essential to discovery and outcome. Mason C; Dunnill P Regen Med; 2007 May; 2(3):227-9. PubMed ID: 17511558 [No Abstract] [Full Text] [Related]
25. How to revive breakthrough innovation in the pharmaceutical industry. Munos BH; Chin WW Sci Transl Med; 2011 Jun; 3(89):89cm16. PubMed ID: 21715677 [TBL] [Abstract][Full Text] [Related]
26. An industrial perspective on contemporary applications of PBPK models in drug discovery and development. Smith BJ Biopharm Drug Dispos; 2012 Mar; 33(2):53-4. PubMed ID: 22407480 [No Abstract] [Full Text] [Related]
27. [Drug development in Japan from the viewpoints of global pharmaceutical companies]. Seriu T Rinsho Ketsueki; 2009 Jul; 50(7):556-62. PubMed ID: 19638723 [No Abstract] [Full Text] [Related]
28. [Open innovation for Japanese pharmaceutical companies]. Hoshino T Nihon Yakurigaku Zasshi; 2013 Oct; 142(4):184-9. PubMed ID: 24107523 [No Abstract] [Full Text] [Related]
29. Can open-source drug R&D repower pharmaceutical innovation? Munos B Clin Pharmacol Ther; 2010 May; 87(5):534-6. PubMed ID: 20407458 [TBL] [Abstract][Full Text] [Related]
30. Marc Kirschner. Interview by Asher Mullard. Kirschner M Nat Rev Drug Discov; 2011 Dec; 10(12):894. PubMed ID: 22129982 [No Abstract] [Full Text] [Related]
31. Drug development research: diabetes favored over cardiovascular disease? Suckling K Curr Opin Investig Drugs; 2009 Mar; 10(3):217-9. PubMed ID: 19333877 [No Abstract] [Full Text] [Related]
32. Deal watch: Trends in discovery externalization. Mayhew S Nat Rev Drug Discov; 2010 Mar; 9(3):183. PubMed ID: 20190781 [No Abstract] [Full Text] [Related]
33. Trial watch: Clinical trial cycle times continue to increase despite industry efforts. Martin L; Hutchens M; Hawkins C Nat Rev Drug Discov; 2017 Mar; 16(3):157. PubMed ID: 28184041 [No Abstract] [Full Text] [Related]
34. Open access chemical and clinical probes to support drug discovery. Edwards AM; Bountra C; Kerr DJ; Willson TM Nat Chem Biol; 2009 Jul; 5(7):436-40. PubMed ID: 19536100 [TBL] [Abstract][Full Text] [Related]
35. European lead factory opens for business. Mullard A Nat Rev Drug Discov; 2013 Mar; 12(3):173-5. PubMed ID: 23449292 [No Abstract] [Full Text] [Related]
36. Interview with Lisa Shipley. Interviewed by Lisa Parks. Shipley L Bioanalysis; 2013 Aug; 5(15):1819-20. PubMed ID: 23905854 [TBL] [Abstract][Full Text] [Related]
37. The shrinking of the knowledge base - what is the impact of this on the speed and security of drug development? Branthwaite P Drug Discov Today; 2010 Jan; 15(1-2):1-2. PubMed ID: 19837187 [No Abstract] [Full Text] [Related]
38. Virtual drug discovery with the rise of Chinese CROs. Zhang MQ Drug Discov Today; 2010 Sep; 15(17-18):693-7. PubMed ID: 20685343 [No Abstract] [Full Text] [Related]